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long-term outcomes and overall cost savings relative to meniscectomy, making it the 
dominant treatment strategy from a health-economic perspective.
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OBJECTIVES: Gout is the most common and progressive arthritic condition. Its sever-
ity is assumed to have implications for the humanistic and economic burden of 
the illness. The objective of this study is to examine the burden of gout between 
patients with and without tophi using electronic health records (EHR). METHODS: 
The Humedica EHR database was searched starting on January 1, 2008 through 
February 28, 2013 for patients having an initial gout diagnosis (ICD-9 274.xx) and 
a confirmatory gout diagnosis at least 30 days later. Deidentified patients with 
enrollment from 6-months pre/12-months post initial gout diagnosis and at least 
one serum uric acid (SUA) level were included in the study. Patients (n= 933) with a 
diagnosis of tophaceous gout (274.03, 274.81, and 274.82) during the 12-months post-
index period were compared to all other gout (non-tophaceous) patients (n= 45,512). 
Demographic characteristics and comorbidities, SUA levels, and use of colchicine 
for acute flares during the 12-months post-index period were compared using chi-
square tests. RESULTS: Gout patients with tophi were more likely to be female 
(p< 0.01) and have uncontrolled (SUA= 6-8) or severely uncontrolled (SUA = > 10) SUA 
(p< 0.0001) than patients without tophi. Colchicine use was higher in patients with 
tophi (p< .0001). There were significantly higher levels of cardiovascular comorbidities 
in the gout patients with tophi vs those without: hypertension (p< 0.05), myocardial 
infarction (p< 0.01), atherosclerosis (p< 0.0001), dyslipidemia (p< 0.0001), peripheral 
arterial disease (p< 0.0001), congestive heart failure (p< 0.0001), chronic heart disease 
(p< 0.0001), cardiomyopathy(p< 0.0001), ischemic and valvular heart disease (p< 0.0001) 
and left ventricular hypertrophy (p< 0.001). Gout patients with tophi had higher levels 
of chronic kidney disease, Stages 3-5, (p< 0.0001), osteoarthritis (p< 0.0001), rheuma-
toid arthritis (p< 0.0001). CONCLUSIONS: Gout patients with tophi had significantly 
greater burden of disease and greater frequency of comorbidities than those without. 
Preventing the development of tophi may reduce comorbidities and frequency of 
colchicine use and warrants further investigation.
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OBJECTIVES: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with 
skin psoriasis. PsA causes swelling, stiffness and pain in joints, it may also affect 
the spine, ankles and wrists. It is also associated with decreased quality-of-life in 
its patients. Treatment of PsA includes both pharmacological and non-pharmaco-
logical treatments. The research aims to estimate the economic burden of PsA in 
Taiwan. METHODS: The National Health Insurance Research Database (NHIRD), 
a claims-based dataset encompassing 99% of Taiwan’s population, was applied. 
The database measures direct costs to the healthcare system and does not take 
into account indirect costs such as absenteeism or loss of productivity. We used a 
micro-costing approach for direct health care costs by estimating the quantities 
and prices of cost categories. Direct costs included surgeries, ward usage, medical 
devices and materials, lab tests, PUVA therapy and medications. The costs and 
quantities of the direct economic burden were calculated based on 2011 data of 
NHIRD. We identified PsA patients and a control cohort matched 1:4 on demographic 
and clinical covariates to calculate the incremental cost related to PsA. RESULTS: 
A total of 4,053 PsA patients were included in the database with incremental total 
direct cost of $13,282,615. This resulted in an average incremental direct cost of 
$3,277 per PsA patient. Direct costs were mostly influenced by medication costs 
($11,991,479; 90.28%), while lab tests ($576,403; 4.34%), PUVA therapy ($348,741; 
2.63%), surgery ($150,471; 1.13%), ward usage ($130,978; 0.99%) and medical devices/
materials ($84,543; 0.64%) made up the balance. Within medication costs, biologic 
and tablet disease-modifying anti-rheumatic drugs accounted for 45% and 22% 
of all medication costs, respectively. CONCLUSIONS: Our findings highlight the 
significant economic burden PsA places on Taiwan’s economy. The direct costs of 
PsA in Taiwan are driven by medication costs and lab tests. Efficient management 
of PsA could reduce the economic impact of the disease.
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OBJECTIVES: Rheumatoid Arthritis (RA) is a chronic inflammatory disease which 
destroys synovial joints and generates pain; RA could disable patients and could be 
the cause of premature death. Its prevalence for Chile has been estimated in 0.46% 
(IC 95% 0.24-0.8). Available drugs for treatment include conventional synthetic 
Disease-Modifying Antirheumatic Drugs (csDMARDs), biological therapies and a 
new oral janus kinase inhibitor drug approved for treatment after failure of csD-
MARDs: tofacitinib. The aim of this study is to determine the direct costs associ-
ated with available therapies after csDMARDs failure. METHODS: The analysis was 
made from third payer perspective with a time horizon of one year. Costs baskets 
were constructed, considering the costs of diagnosis, treatment and monitoring 
of the intervention and validated with rheumatologists. Drug costs were obtained 
from public tenders and official reports. Comparators were: tofacitinib (5mg twice/
OBJECTIVES: To assess the influence of different treatment schemes of post-stroke 
spasticity on societal costs in Russia. METHODS: Analytical model of decision-
making in Microsoft Excel 2013 was designed for assessing an influence of local 
standard therapy and different types of botulinum toxin (abobotulinumtoxinA, 
onabotulinumtoxinA, incobotulinumtoxinA) on the societal costs. Societal costs 
included: disability pensions, temporary disability benefit and GDP loss of due to 
loss of working force in case post-stroke spasticity. Disability assessment scale 
score was used as efficacy criteria. The main domains of this scale (0 – normal life, 
3 – full disability) were compared with Russian disability group system (1st group 
of disability – severe grade, 3d group – mild grade). According to the information 
retrieval using Ministry of trade and social development database and clinical tri-
als data it was found that in 2014 out of 287,314 people with post-stroke spastic-
ity there were 12,7% disabled people of 1st grade, 32,7% of 2nd one and 34,6% of 
3d one. 20% of people have no disability group. For reference, accepted exchange 
rate was 1 US$ = 60,29 RUB. RESULTS: Therapy with abobotulinumtoxinA allows to 
decrease disability level with 16%-efficacy, therapy with onabotulinumtoxinA with 
12,6 %-efficacy, standard therapy with 3,3%-efficacy. Consequently, societal costs 
economy for whole population of post-stroke spasticity patients for one year is US$ 
378,97 million higher compared with standard therapy, US$ 119,21 million higher 
compared with onabotulinumtoxinA treatment scheme, and US$ 129,47 million 
higher compared with incobotulinumtoxinA treatment scheme. CONCLUSIONS: 
AbobotulinumtoxinA treatment scheme shows more prominent decrease of disabil-
ity level in post-stroke spasticity patients in Russia and allows to decrease societal 
costs to a greater extent compared with other alternatives. That fact makes abobo-
tulinumtoxinA more beneficial from the societal costs perspective compared with 
other treatment schemes.
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OBJECTIVES: The full economic impact of brand to generic switching within OA 
has not been well studied. The purpose of this study was to measure switch rates 
from the branded COX-2 inhibitor Celebrex (celecoxib) to generic non-steroidal anti-
inflammatory drugs (NSAIDs) and compare economic outcomes between switched 
and persistent patients with OA. METHODS: This retrospective claims analysis used 
MarketScan®2009 to 2013 data to extract a cohort of incident adult OA (ICD-9-CM: 715.
xx) patients prescribed with Celebrex. Patients included had 12-month continuous 
enrollment before (pre-index) and ≥ 6 months after their first (index) Celebrex claim 
and had ≥ 2 Celebrex claims. Persistence was measured as time to the first prescrip-
tion gap of ≥ 30 days; treatment switch to generic NSAIDs required a fill for generic 
NSAIDs within 30 days of discontinuing Celebrex. Annualized healthcare resource 
utilization (HCRU) and direct costs were compared descriptively between patients 
switched to generic NSAIDs and persistent patients within propensity score matched 
cohorts. RESULTS: The 65,530 included patients had mean±SD age 61±11.9 years 
and were 62.5% female. By end of follow-up, 6,783 (10.35%) patients were persistent 
on Celebrex. The majority of patients (54,554, 83.3%) discontinued Celebrex without 
switching and 3,475 (5.3%) switched to generic NSAIDs (median time to switch or 
discontinuation was 2.96 months). After matching (N= 3,298 per cohort), persistent 
users had less HCRU and significantly lower mean total costs ($23,949 vs $20,378, P < 
.001) compared to switched patients. Mean OA-related costs were similar for persis-
tent vs switched patients ($5,755 vs $5,910, P= 0.63), with persistent patients having 
higher mean drug costs ($2,693 vs. $1,098, P< .001) but lower mean inpatient ($2,370 vs 
$3,622, P< .001) and outpatient costs ($848 vs $1,035, P< .001). CONCLUSIONS: Despite 
lower drug costs, switching from Celebrex to generic NSAIDs was associated with 
greater inpatient and outpatient visits, leading to higher overall costs for OA patients.
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OBJECTIVES: Meniscal tears are the most common knee condition requiring surgery, 
and represent a substantial disease burden with long-term clinical and cost implica-
tions. Research performed over the last two decades has shed light on the success 
rates of the two primary treatment strategies—partial meniscectomy and meniscus 
repair. However, only limited information is available about the long-term costs and 
effects of these strategies. Our objective was to assess the long-term cost-effective-
ness of meniscus repair compared to meniscectomy. METHODS: We constructed 
a decision-analytic Markov disease progression model, taking into account index 
strategy-specific failure rates as well as treatment-specific probabilities for the devel-
opment of osteoarthritis (OA) and subsequent total knee replacement (TKR). Failure 
rates and OA incidence were derived from a review of controlled and uncontrolled 
studies as well as recent meta-analyses. Costs were derived from current 2014 U.S. 
national average reimbursement amounts and the published literature. We computed 
the 20-year incremental cost-effectiveness ratio (ICER) and relative event risks in a 
cohort of 38 year-old patients, 21% of whom were female. RESULTS: Over the 20 
year horizon, meniscus repair was associated with an gradual increase in discounted 
QALYs from 12.84 to 12.99 compared to meniscectomy, at overall discounted savings 
of $2,598, making it the dominant index procedure strategy. While the meniscus 
repair strategy was associated with an increased failure rate (RR of 6.12), it led to 
substantial reductions in OA and TKR incidence (16.0% vs. 29.4% and 8.5% vs. 16.1%, 
respectively). Clinical benefit and cost-effectiveness further improved with longer-
follow-up. CONCLUSIONS: Our model-based projection suggests that meniscus 
repair, despite substantially higher initial failure rates, is associated with improved 
